BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/14/2017 12:28:19 AM | Browse: 1053 | Download: 1236
 |
Received |
|
2017-06-26 01:48 |
|
Peer-Review Started |
|
2017-06-27 08:59 |
|
To Make the First Decision |
|
2017-08-07 01:03 |
|
Return for Revision |
|
2017-08-07 02:38 |
|
Revised |
|
2017-08-24 14:24 |
|
Second Decision |
|
2017-09-06 08:23 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2017-09-16 19:03 |
|
Articles in Press |
|
2017-09-16 19:03 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2017-12-08 03:05 |
|
Publish the Manuscript Online |
|
2017-12-14 00:28 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Neoadjuvant therapy for resectable pancreatic cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Sheikh Hasibur Rahman, Robin Urquhart and Michele Molinari |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Michele Molinari, MD, MSc, Senior Scientist, Surgeon, Department of Surgery, University of Pittsburgh Medical Center, 3459 Fifth Avenue, N758, Pittsburgh, PA 15213, United States. molinarim@upmc.edu |
| Key Words |
Pancreatic adenocarcinoma; Neoadjuvant chemotherapy; Neoadjuvant chemoradiation therapy; Meta-analysis; Decision analysis; Borderline resectable; Locally advanced; Randomized controlled trial; Phase Ⅰ trial; Phase Ⅱ trial; Phase Ⅲ trial |
| Core Tip |
The use of neoadjuvant therapy for patients with resectable pancreatic cancer (PC) has been used by an increasing number of cancer centers around the world. The main rationale of using neoadjuvant therapies in resectable PC is the hope that patients’ likelihood of long-term overall survival will benefit from the chemo or chemoradiation therapy administered when their overall conditions allow them to tolerate the treatment. At this time, there is no phase Ⅲ trial to support the use of neoadjuvant therapies in resectable PC. Without strong scientific evidence supporting the theoretical advantages of neoadjuvant therapies, these potential benefits might turn out not to be worth the risk of tumors progression while waiting for surgery. |
| Publish Date |
2017-12-14 00:28 |
| Citation |
Rahman SH, Urquhart R, Molinari M. Neoadjuvant therapy for resectable pancreatic cancer. World J Gastrointest Oncol 2017; 9(12): 457-465 |
| URL |
http://www.wjgnet.com/1948-5204/full/v9/i12/457.htm |
| DOI |
http://dx.doi.org/10.4251/wjgo.v9.i12.457 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
